Savara Inc (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory disease, is on track to report top-line data from IMPALA-2 trial this quarter.
IMPALA-2, a Phase III, 48-week placebo-controlled trial, is evaluating the effectiveness of Molgramostim nebulizer solution, a novel inhaled biologic, for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com